@article{d5123d8df3044b019051b342ec2f373d,
title = "Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia",
abstract = "The neurobiological effects of clozapine are under characterised. We examined the effects clozapine treatment on subcortical volume and cortical thickness and investigated whether macrostructural changes were linked to alterations in glutamate or N-acetylaspartate (NAA). Data were acquired in 24 patients with treatment-resistant schizophrenia before and 12 weeks after switching to clozapine. During clozapine treatment we observed reductions in caudate and putamen volume, lateral ventricle enlargement (P < 0.001), and reductions in thickness of the left inferior temporal cortex, left caudal middle frontal cortex, and the right temporal pole. Reductions in right caudate volume were associated with local reductions in NAA (P = 0.002). None of the morphometric changes were associated with changes in glutamate levels. These results indicate that clozapine treatment is associated with subcortical volume loss and cortical thinning and that at least some of these effects are linked to changes in neuronal or metabolic integrity.",
author = "Fanni Krajner and Laila Hadaya and Grant McQueen and Kyra-Verena Sendt and Amy Gillespie and Alessia Avila and John Lally and Milly Hedges and Kelly Diederen and Oliver Howes and Gareth Barker and David Lythgoe and Matthew Kempton and Philip McGuire and James Maccabe and Alice Egerton",
note = "Funding Information: This work was funded by the Medical Research Council, UK, Grant MR/L003988/1 to A.E. and by the European Community{\textquoteright}s Seventh Framework Programme (FP7/2007–2013), grant 279227 to J.H.M. This study presents independent research funded in part by the National Institute for Health Research (NIHR), Biomedical Research Centre at South London, and Maudsley National Health Service (NHS) Foundation Trust and King{\textquoteright}s College London. Funding Information: G.J.B. receives honoraria for teaching from General Electric Healthcare, who also part-fund a PhD studentship. A.A. is receiving funding from the Portuguese Foundation for Science and Technology (FCT). J.H.M. has received investigator-initiated grant support from H Lundbeck, independently of this work. O.D.H. is a part-time employee of H Lundbeck A/s. He has received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Heptares, Global Medical Education, Invicro, Jansenn, Lundbeck, Neurocrine, Otsuka, Sunovion, Recordati, Roche and Viatris/Mylan. The remaining authors report no relevant financial interests or potential conflicts of interest. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = mar,
day = "2",
doi = "10.1038/s41537-022-00230-2",
language = "English",
volume = "8",
journal = "NPJ SCHIZOPHRENIA",
issn = "2334-265X",
publisher = "Nature Publishing Group",
number = "1",
}